SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma
Feng, B.-J.; Fatema, K.; Nix, D. A.; Atkinson, A.; Caparas, C.; Stubben, C. J.; Lum, D. H.; Parnell, T. J.; Carroll, C.; Grass, G. D.; Graham, L.; Singer, E. A.; Nepple, K. G.; Manojlovic, Z.; Kauffman, E.; King, J. M.; Ghodoussipour, S.; Hensley, P.; Viscuse, P. V.; Ayanambakkam, A.; Churchman, M. L.; Swami, U.; Agarwal, N.; Cairns, B.; Gupta, S.
Show abstract
PurposeSWI/SNF (BAF) chromatin remodeling complex alterations are common in urothelial carcinoma, yet no biomarker-directed therapeutic strategies have been established for this population. We investigated whether BAF alterations delineate a biologically distinct, therapeutically actionable urothelial carcinoma subtype. Experimental DesignWe performed integrative genomic and transcriptomic analyses of 792 urothelial carcinoma tumors from the Oncology Research Information Exchange Network (ORIEN) and validated findings in the TCGA-BLCA cohort. Mechanistic studies incorporated RNA sequencing and ATAC-seq following histone deacetylase (HDAC) inhibition. Functional dependencies were assessed using patient-derived xenograft organoids and cell line models. Clinical relevance was explored in a biomarker-enriched investigator-initiated trial. ResultsApproximately half of urothelial carcinoma tumors exhibited BAF alterations, defining a previously unrecognized chromatin-altered molecular subtype characterized by activation of proliferative programs, loss of lineage identity, and altered metabolic signaling. This subtype was enriched for transcriptomic programs associated with HDAC inhibitor sensitivity and depleted of HDAC inhibitor resistance signatures. Mechanistically, HDAC inhibition induced widespread chromatin remodeling with reduced accessibility at AP-1 and TEAD-associated regions, and downregulation of E2F- and MYC-driven transcriptional networks. Functional studies confirmed enhanced HDAC inhibition sensitivity in ARID1A-mutated cell lines and a patient-derived organoid model. Early clinical observations demonstrated a durable responder treated with HDAC inhibitors and immunotherapy. ConclusionsBAF alterations define a chromatin-dependent tumor state in urothelial carcinoma that is selectively vulnerable to HDAC inhibition. Integrating genomic, epigenomic, functional, and early clinical evidence, these findings provide a rationale for biomarker-enriched clinical trials and HDAC inhibitor-based combination strategies in urothelial carcinoma.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer 93%
- Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification 92%
- Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer 91%
Similar papers in this journal
- Archetype analysis of lung adenocarcinoma premalignancy links heterogeneity in premalignant lesions to diverging features of invasive disease 91%
- Intrinsic epigenetic state of primary osteosarcoma drives metastasis 90%
- Combinations of genomic alterations and immune microenvironmental features associate with patient survival in multiple cancer types 89%
Similar papers in this journal
- ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastrophe 90%
- Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition 90%
- Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access 90%
Similar papers in this journal
- Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors 91%
- NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition 91%
- A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells 90%
Similar papers in this journal
- Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer 91%
- Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers 91%
- Regulatory FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.